Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

59 results about "Galectin" patented technology

Galectins are a class of proteins that bind specifically to β-galactoside sugars, such as N-acetyllactosamine (Galβ1-3GlcNAc or Galβ1-4GlcNAc), which can be bound to proteins by either N-linked or O-linked glycosylation. They are also termed S-type lectins due to their dependency on disulphide bonds for stability and carbohydrate binding. There have been 15 galectins discovered in mammals, encoded by the LGALS genes, which are numbered in a consecutive manner. Only galectin-1, -2, -3, -4, -7, -8, -9, -10 and -12 have been identified in humans. Galectin-5 and -6 are found in rodents, whereas galectin-11, -14 and -15 are uniquely found in sheep and goats. Members of the galectin family have also been discovered in other mammals, birds, amphibians, fish, nematodes, sponges, and some fungi. Unlike the majority of lectins they are not membrane bound, but soluble proteins with both intra- and extracellular functions. They have distinct but overlapping distributions but found primarily in the cytosol, nucleus, extracellular matrix or in circulation. Although many galectins must be secreted, they do not have a typical signal peptide required for classical secretion. The mechanism and reason for this non-classical secretion pathway is unknown.

Anti-galectin-9 antibodies and uses thereof

Disclosed herein are anti-Galectin-9 antibodies and methods of using in modulating (e.g., increasing) immune responses in a subject, either taken alone or in combination with an immune checkpoint inhibitor, such as a PD-1 inhibitor.
Owner:NEW YORK UNIV +1

A galectin 10 crystal and an antibody igy and a pharmaceutical preparation prepared therefrom

ActiveCN115785245BEgg immunoglobulinsAerosol deliveryAntigenSide effect
The application provides a galactoside agglutinin 10 (Gal10) crystal and a preparation method and prepared antibody IgY and a pharmaceutical preparation thereof, and belongs to the technical field of medicines. The application uses the galactoside agglutinin 10 crystal as an antigen to prepare an egg yolk neutralizing antibody IgY capable of dissolving the Gal10 crystal, has the effects of improving rhinitis or asthma of a patient, preventing and treating rhinitis and asthma, and is safe, has no side effects, has a long-lasting curative effect, and has no drug resistance, thereby providing a safe, simple, hygienic, effective, economic and personalized treatment mode for prevention and treatment of rhinitis and asthma, and having a high market value.
Owner:SHANGHAI BIO-FULL BIOTECH CO LTD

Compound of Galectin-3 and EGFR double-target inhibitor and application thereof

The invention discloses a compound of a Galectin-3 and EGFR (Epidermal Growth Factor Receptor) double-target inhibitor in the technical field of biological medicines, and the compound disclosed by the invention not only shows a relatively strong Galectin-3 and EGFR binding effect, but also has certain in-vitro anti-hepatic fibrosis activity, and can be applied to Galectin-3 and EGFR target related tumor diseases. As a double-target anti-hepatic fibrosis candidate compound based on Galectin-3 and EGFR, which is reported for the first time, the compound has further values of research and development and research of original new drugs based on double targets of Galectin-3 and EGFR.
Owner:ZHONGSHAN INST FOR DRUG DISCOVERY SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI +1

Composition for preventing or treating lupus, comprising recombinant stabilized galectin 9 protein

The present invention relates to a composition for preventing or treating lupus or glomerulonephritis comprising a recombinant stabilized Galectin-9 protein. Specifically, the recombinant stabilized Galectin-9 protein of the present invention has been confirmed to exhibit safety in a systemic lupus erythematosus (SLE) animal model, reduce skin lesions, lymphadenopathy, and proteinuria caused by lupus, ameliorate lupus nephritis and glomerulonephritis, and decrease the concentration of anti-dsDNA antibodies in plasma. Accordingly, the recombinant stabilized Galectin-9 protein of the present invention can be effectively used as an active ingredient in a composition for preventing or treating lupus or glomerulonephritis.
Owner:GBIOLOGICS INC

Galectin MsGal-3 and application thereof in resisting MSRV infection in micropterus salmoides

PendingCN121108289APeptide/protein ingredientsAntiviralsEscherichia coliRhabdovirus carpio
The invention discloses a galectin MsGal-3 and an application of the galectin MsGal-3 in resisting MSRV infection in micropterus salmoides. Galectin MsGal-3 (the accession number is PV454561) is obtained through screening and identification from a liver transcriptome of micropterus salmoides, a target gene is synthesized, plasmids are constructed, then an escherichia coli E.coli expression strain BL21 is adopted for induced expression, and MsGal-3 protein is obtained through purification and can be used for preventing and treating micropterus salmoides rhabdovirus infection.
Owner:ZHEJIANG SCI-TECH UNIV

Modified Anti-galectin-9 antibody and uses thereof

Provided herein are affinity matured anti-galectin-9 (Gal9) antibodies. The antibodies have improved binding affinity to Gal9. Also provided herein are method of use of the affinity matured anti-Gal9 antibodies, including methods of treatment of cancer, methods of rescuing or promoting effector T cell proliferation, methods of enhancing effector T cell activity, and / or of identifying and treating cancer in a subject including the administration of the anti-Gal9 antibodies described herein. Also provided are polynucleotides encoding the heavy chain or the light chain or the antigen-binding portion thereof described herein, and vectors, especially expression vectors, including the polynucleotides described herein.
Owner:FIBROGEN INC +1

Novel galactoside inhibitor of galectins

PCT designated stageWO2025252743A1Organic active ingredientsSugar derivativesPharmacologyGalactoside
The present invention relates to a high affinity galectin-3 inhibitor alpha-D-galactopyranose derivative of formula (I), a pharmaceutical salt or solvate thereof, for use in treatment of inflammation.
Owner:GALECTO BIOTECH

A combination drug for preventing and / or treating prostate cancer, use thereof, and a pharmaceutical composition

The present application belongs to the field of chemical medicine, and particularly relates to a combined drug for preventing and / or treating prostate cancer, use and pharmaceutical composition thereof. The combined drug of the present application is an immune cell with enhanced infiltration degree and a galectin-1 inhibitor; the immune cell with enhanced infiltration degree is a natural killer (NK) cell with TTTY15-USP9Y chimera RNA knocked out, which can increase the infiltration degree and anti-tumor activity of the NK cell in the prostate cancer microenvironment, and the activated NK cell has stronger killing effect on tumor cells in vitro. The present application combines the immune cell with enhanced infiltration degree and the galectin-1 inhibitor, and the combination shows synergistic effect in treating prostate cancer, and has wide application prospect.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Osteoclast fusion inhibitor and osteoclast fusion inhibitory composition

PendingJP2026087288AAntibody ingredientsAntineoplastic agentsOsteoclasisOsteoclast fusion
To provide an osteoclast fusion inhibitor that is highly effective and has few side effects. [Solution] An osteoclast fusion inhibitor containing an anti-galectin-3 neutralizing antibody as an active ingredient.
Owner:KAKE EDUCATIONAL INSTITUTION +1

Use of citrullinated galectin-1 polypeptides for the preparation of diagnostic products for rheumatoid arthritis

The application discloses application of citrullinated galectin-1 polypeptide in preparation of a rheumatoid arthritis diagnosis product, and belongs to the technical field of rheumatoid arthritis diagnosis. The amino acid sequence of the citrullinated galectin-1 polypeptide is GD-Cit-WSSQQGSKAVYPE; the product is used for detecting the content of anti-citrullinated galectin-1 polypeptide antibody in a biological sample of a patient, and the antibody level is significantly different between RA patients, normal healthy people and other common rheumatic immune disease patients who are easily confused with rheumatoid arthritis. The product has good sensitivity to common RA, RA with normal ESR and CRP, and anti-CCP antibody / RF negative RA patients, and has good supplementary diagnosis value for the diagnosis of RA.
Owner:PEOPLES HOSPITAL PEKING UNIV

Suppression of inflammation associated with implants

Provided herein are methods and compositions for suppressing a foreign body reaction, such as an implant-associated inflammation in a subject, by using an anti-Galectin-3 antibody. Such methods and compositions can be used in various areas applications where an implant is introduced, such as in brain-computer interface (BCI).
Owner:SUNMED THERAPEUTIC LTD

Stabilized formulation comprising recombinant stabilized galectin 9 protein

The present invention relates to a stabilized pharmaceutical formulation comprising a recombinant stabilized galectin-9 protein. More specifically, the invention provides a pharmaceutical formulation with improved stability through the combination of a buffer and a stabilizer.
Owner:GBIOLOGICS INC

Compositions Comprising an Inhibitor of Galectin-3

The present disclosure provides a composition comprising a compound of Formula I, or pharmaceutically acceptable salt thereof, and / or a compound of Formula II, or pharmaceutically acceptable salt thereof, for use in inhibiting Galectin-3. The composition may be for use in the treatment and / or prevention of a disease, disorder, state or condition wherein inhibiting Galectin-3 would be beneficial for the treatment and / or prevention of the disease, disorder, state or condition. The disease, disorder, state or condition may be cancer, cancer metastasis, fibrosis, inflammation, diabetes and / or one or more other disease, disorder, state or condition affected and / or mediated by Galectin-3.
Owner:UNIV OF LIVERPOOL

Anti-galectin-9 antibody and uses thereof

The invention provides humanized monoclonal antibodies against Gal9, and method of using the antibodies to treat cancer, including combination therapy with antagonists of the PD-1 / PD-L1 immune checkpoint.
Owner:HIFIBIO INC(US)

Anti-galectin-9 antibodies and their use

PendingJP2026062750AOrganic active ingredientsAntibacterial agentsAntibody SuppressionEpitope
This invention provides novel human antibodies that bind to human galectin-9, and their therapeutic use in the treatment of cancer. [Solution] Provided are isolated anti-galectin-9 antibodies that bind to epitopes in the glycan recognition domain (CRD) of galectin-9 polypeptides, and methods for using anti-galectin-9 antibodies to inhibit galectin-9-mediated signaling pathways or to eliminate diseased cells expressing galectin-9. Such anti-galectin-9 antibodies may also be used to diagnose and / or treat galectin-9-related diseases, such as autoimmune diseases and solid tumors.
Owner:NEW YORK UNIV +1

Application of OTX008 in treatment of HSV-1 virus infection

The invention discloses an application of OTX008 in the treatment of HSV-1 virus infection. The application verifies that the galectin-1 selective inhibitor OTX008 can remarkably promote activation of an I-type interferon signal channel of a host after virus infection by constructing a mouse model infected by an HSV-1 virus; tissue inflammation damage caused by virus infection can be relieved; the immunopotentiator shows an immunopotentiation effect in mouse peritoneal macrophages. Therefore, the OTX008 disclosed by the invention can be used for promoting the function of an innate immune cell and inhibiting the replication of the HSV-1 virus in the cell; an immune escape strategy of the HSV-1 virus is cracked; the defect of high drug resistance of the traditional HSV-1 virus treatment drug is overcome to a certain extent; according to the application, a new host drug target spot is found, and a good clinical application prospect in resisting HSV-1 virus infection is shown.
Owner:SHANGHAI PUBLIC HEALTH CLINICAL CENT

Treatment of hematological malignancies with antibodies inhibiting galectin-9

PendingCN122349533Asmall doseAntiendomysial antibodiesVenetoclax
Disclosed herein are combination therapies for treating hematological malignancies (e.g., acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)) using an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g., G9.2-17) and one or more chemotherapeutic agents, e.g., a Bcl2 inhibitor such as venetoclax, a hypomethylating agent (HMA), or a combination thereof.
Owner:PURETECH LYT INC

Anti-galectin 3 antibodies and their use in epilepsy and related diseases

Provided herein are antibodies that target Galectin-3. Such antibodies are used in methods of treating epilepsy and related neurological disorders, such as Alzheimer's disease (AD) and Parkinson's disease (PD).
Owner:SUNMED THERAPEUTIC LTD

Compositions comprising galectin-3 inhibitors

The present disclosure provides a composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, and / or a compound of Formula II or a pharmaceutically acceptable salt thereof, for use in inhibiting galectin-3. The composition can be used in the treatment and / or prevention of a disease, disorder, condition, or a state, wherein inhibition of galectin-3 would be beneficial for the treatment and / or prevention of the disease, disorder, condition, or state. The disease, disorder, condition, or state can be cancer, cancer metastasis, fibrosis, inflammation, diabetes, and / or one or more other disease, disorder, condition, or state affected by and / or mediated by galectin-3.
Owner:UNIV OF LIVERPOOL

Composition of novel carbohydrate drug for treatment of human diseases

Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.
Owner:GALECTIN THERAPEUTICS INC

Application of Galectin-3 inhibitor based on tetrahedral framework nucleic acid in treatment of fibrotic diseases

The invention belongs to the technical field of biological medicines, and particularly relates to application of a Galectin-3 inhibitor based on tetrahedral framework nucleic acid to treatment of fibrosis diseases. The invention provides the Galectin-3 inhibitor based on tetrahedral framework nucleic acid through sequence screening, and the Galectin-3 inhibitor has a BiRDS structure, has the capabilities of regulating immune polarization, resisting oxidation and resisting fibrosis at the same time, and has a remarkable effect when being used for treating fibrosis model animals. The Galectin-3 inhibitor based on the tetrahedral framework nucleic acid has a good prospect in the aspect of treating fibrosis diseases.
Owner:SICHUAN UNIV

Galectin-1 / galectin-3 chimeras and multivalent proteins

Described herein are Galectin-1 / Galectin-3 multivalent protein complexes and uses thereof. In some aspects, Galectin-1 / Galectin-3 multivalent protein complexes are useful to treat inflammatory conditions in a subject.
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC

Galactoside inhibitor of galectins

A compound of the general formula I or II. The compound of formula I or II is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
Owner:GALECTO BIOTECH

Novel galactoside inhibitor of galectins

PCT designated stageWO2025252741A1Organic active ingredientsSugar derivativesPharmacologyGalactoside
The present invention relates to a high affinity galectin-3 inhibitor alpha-D-galactopyranose derivative of formula (I), a pharmaceutical salt or solvate thereof, for use in treatment of inflammation.
Owner:GALECTO BIOTECH

Antibodies or antigen-binding fragments thereof and uses thereof

The application provides a target antibody or antigen binding fragment thereof and application thereof, and belongs to the antibody field.The antibody or antigen binding fragment thereof comprises a heavy chain complementarity determining region HCDR, and the HCDR comprises at least one of amino acid sequences selected from SEQ ID NO: 1-18 or an amino acid sequence with at least 80% homology with the amino acid sequences.The antibody or antigen binding fragment thereof can be combined with a TIM-1 protein with high specificity and affinity, increase the blocking of TIM-1 activity, make the TIM-1 interact with ligands such as phosphatidylserine, TIM-4 and galectin-9, and enhance the immune response.
Owner:UNIV OF SCI & TECH OF CHINA

Galectin-3 antigenic epitope peptides, antigens, antibodies and chemiluminescent kits

The application provides a Galectin-3 antigen epitope peptide, an antigen, an antibody and a chemiluminescence kit, relates to the technical field of biological detection, the antigen epitope peptide is an antigen epitope sequence 196-225 amino acid of Galectin-3, and the amino acid sequence is shown as SEQ ID NO:1.Based on the antigen epitope peptide, the application further provides corresponding antigens, antibodies and the application of the antigens in the preparation of a Galectin-3 detection kit.Compared with common kits, the chemiluminescence kit has high sensitivity, can detect target substances with extremely low concentration, is suitable for trace analysis and ensures the accuracy of detection results.The reaction system is simple, and the operation is convenient;only by adding an appropriate amount of reagent, the chemiluminescence reaction can be completed, and the detection efficiency is greatly improved.The chemiluminescence kit has good specificity, can effectively exclude interfering substances and ensures the accuracy of detection results.Finally, the chemiluminescence kit has strong portability, is convenient for on-site detection in different places and can quickly obtain accurate results.
Owner:AFFILIATED HOSPITAL OF NANTONG UNIV

Galactorhamnoside compound as well as preparation method and application thereof

The invention belongs to the technical field of chemical medicines, and particularly relates to a galactorhamnoside compound as well as a preparation method and application thereof. The structural formula of the compound is selected from any one of the following formulas; ; or; in the formula, R1 ', R1 '', R1''' and R2 'are independently selected from-H, fluorine-substituted benzoyl, fluorine-substituted benzyl, nitro-substituted benzoyl or nitro-substituted benzyl. The galactorhamnoside compound is used as a galectin-3 inhibitor to be applied to preparation of anti-pulmonary fibrosis drugs and anti-chronic / acute myelogenous leukemia drugs. Particularly, the TGF-beta-induced A549 (human lung epithelial cell) fibrosis can be obviously inhibited; the obvious lethality is realized on NB4 and K562 cells.
Owner:JINAN CENTER HOSPITAL

Galectin-targeting immunotherapy

The present disclosure provides a virus like particle comprising a viral structural protein and a galectin epitope peptide, and a composition or vaccine comprising thereof, its use in a medicine, particularly in an immunotherapy.
Owner:VLP THERAPEUTICS LLC